SCHEMBL7410539

SCHEMBL7410539

CC(N)C(=O)NOCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.58
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
CTRB1 P17538 3/20 0.55
XIAP P98170 1/20 0.47
SLC1A3 P43003 2/20 0.46
SLC1A2 P43004 2/20 0.46
SLC1A1 P43005 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7372749 0.98 LTA4H (0.57) LTA4HNPC1RAB9ACTRB1XIAP
Hydrochloric Acid SCHEMBL7372746 0.98 LTA4H (0.57) LTA4HNPC1RAB9ACTRB1XIAP
Hydrochloric Acid SCHEMBL6739961 0.98 LTA4H (0.57) LTA4HNPC1RAB9ACTRB1XIAP
SCHEMBL7381215 0.87 NPC1 (0.54) LTA4HNPC1RAB9ACTRB1SLC1A3
SCHEMBL21122288 0.87 NPC1 (0.54) LTA4HNPC1RAB9ACTRB1SLC1A3
SCHEMBL27576935 0.86 NPC1 (0.57) LTA4HNPC1RAB9A
Hydrochloric Acid SCHEMBL20516461 0.85 NPC1 (0.53) LTA4HNPC1RAB9ACTRB1SLC1A3
Hydrochloric Acid SCHEMBL20516460 0.85 NPC1 (0.53) LTA4HNPC1RAB9ACTRB1SLC1A3
SCHEMBL13386551 0.85 NPC1 (0.56) LTA4HNPC1RAB9ACTRB1MEN1
SCHEMBL28889039 0.85 NPC1 (0.56) LTA4HNPC1RAB9ACTRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6262040-B1 Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) PFIZER INC 2001-07-17 US claimed
US-9567302-B2 Carbamate compounds and of making and using same ABIDE THERAPEUTICS, INC. (US) 2017-02-14 US disclosed
US-20150080364-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME ABIDE THERAPEUTICS, INC. (US) 2015-03-19 US disclosed
US-6262040-B1 Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) PFIZER INC 2001-07-17 US disclosed
EP-0931075-A1 INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) PFIZER INC. (US) 1999-07-28 EP disclosed
WO-1998009961-A1 INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) PFIZER INC. (US) 1998-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080364-A1 CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME CPS1, FABP4, VHL LTA4H 3143/4885NPC1 1062/4885RAB9A 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.